NO124840B - - Google Patents
Download PDFInfo
- Publication number
- NO124840B NO124840B NO2340/68A NO234068A NO124840B NO 124840 B NO124840 B NO 124840B NO 2340/68 A NO2340/68 A NO 2340/68A NO 234068 A NO234068 A NO 234068A NO 124840 B NO124840 B NO 124840B
- Authority
- NO
- Norway
- Prior art keywords
- vaccine
- ribonucleic acid
- antigen
- cell
- informative
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 claims description 31
- 229920002477 rna polymer Polymers 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 210000004671 cell-free system Anatomy 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000000185 hemagglutinin Substances 0.000 description 7
- 239000002054 inoculum Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 101710154606 Hemagglutinin Proteins 0.000 description 5
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 5
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 5
- 101710176177 Protein A56 Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000282560 Macaca mulatta Species 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 241000588807 Bordetella Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEJ0033936 | 1967-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO124840B true NO124840B (nl) | 1972-06-12 |
Family
ID=7204943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2340/68A NO124840B (nl) | 1967-06-19 | 1968-06-15 |
Country Status (13)
| Country | Link |
|---|---|
| AT (1) | AT282821B (nl) |
| BE (1) | BE716806A (nl) |
| BR (1) | BR6899970D0 (nl) |
| CH (1) | CH513241A (nl) |
| DE (1) | DE1617545C2 (nl) |
| DK (1) | DK119724B (nl) |
| ES (1) | ES355121A1 (nl) |
| FR (2) | FR1588820A (nl) |
| GB (1) | GB1229888A (nl) |
| IE (1) | IE32140B1 (nl) |
| IL (1) | IL30168A (nl) |
| NL (1) | NL6808486A (nl) |
| NO (1) | NO124840B (nl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE754934A (fr) * | 1969-08-16 | 1971-02-17 | Jachertz Diether | Procede de production enzymatique d'arn-messager |
| GB1594097A (en) | 1976-12-16 | 1981-07-30 | Int Inst Of Differentiation | Production of specific immune nucleic acids cell dialysates and antibodies |
| DE3115559A1 (de) * | 1981-04-16 | 1982-10-28 | Kommanditgesellschaft Schwarzhaupt, 5000 Köln | Hochgereinigte informatorische ribonukleinsaeure (i-rns), verfahren zur herstellung und verwendung derselben |
| GB2216416B (en) * | 1988-03-11 | 1992-06-24 | Sandoz Ltd | Nucleobase source for the stimulation of the immune system |
| US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
-
1967
- 1967-06-19 DE DE1617545A patent/DE1617545C2/de not_active Expired
-
1968
- 1968-06-12 IL IL30168A patent/IL30168A/en unknown
- 1968-06-15 NO NO2340/68A patent/NO124840B/no unknown
- 1968-06-17 IE IE713/68A patent/IE32140B1/xx unknown
- 1968-06-17 NL NL6808486A patent/NL6808486A/xx unknown
- 1968-06-17 CH CH893668A patent/CH513241A/de not_active IP Right Cessation
- 1968-06-17 AT AT576668A patent/AT282821B/de not_active IP Right Cessation
- 1968-06-18 DK DK286268AA patent/DK119724B/da unknown
- 1968-06-18 ES ES355121A patent/ES355121A1/es not_active Expired
- 1968-06-19 FR FR1588820D patent/FR1588820A/fr not_active Expired
- 1968-06-19 BR BR199970/68A patent/BR6899970D0/pt unknown
- 1968-06-19 GB GB1229888D patent/GB1229888A/en not_active Expired
- 1968-06-19 BE BE716806D patent/BE716806A/xx unknown
- 1968-09-18 FR FR166589A patent/FR7781M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE1617545C2 (de) | 1983-11-03 |
| ES355121A1 (es) | 1969-11-16 |
| DE1617545A1 (de) | 1971-04-01 |
| NL6808486A (nl) | 1968-12-20 |
| FR7781M (nl) | 1970-03-23 |
| FR1588820A (nl) | 1970-03-16 |
| BE716806A (nl) | 1968-12-19 |
| BR6899970D0 (pt) | 1973-02-13 |
| IL30168A0 (en) | 1968-08-22 |
| GB1229888A (nl) | 1971-04-28 |
| IL30168A (en) | 1973-05-31 |
| AT282821B (de) | 1970-07-10 |
| IE32140L (en) | 1968-12-19 |
| DK119724B (da) | 1971-02-15 |
| CH513241A (de) | 1971-09-30 |
| IE32140B1 (en) | 1973-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yewdell et al. | Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule | |
| US20090142377A1 (en) | Immunogenic compositions | |
| CN101262881A (zh) | 通过交叉β结构的佐剂化 | |
| Ginsberg | Characteristics of the New Respiratory Viruses (Adenoviruses) I. Qualitative and Quantitative Aspects of the Neutralization Reaction | |
| NO124840B (nl) | ||
| ES2560452T3 (es) | Vacuna de IPV-DPT | |
| Calnek et al. | Some characteristics of cell-free preparations of Marek's disease virus | |
| DK154749B (da) | Fremgangsmaade til fremstilling af en influenzavirusvaccine i en flydende cellekultur | |
| CN1059471A (zh) | 副鸡嗜血杆菌疫苗 | |
| Smith et al. | The relationship between rubella hemagglutination inhibition antibody (HIA) and rubella induced in vitro lymphocyte tritiated thymidine incorporation | |
| JPH05501401A (ja) | 組換え微生物との転移増殖によるワクチン又はトキソイド製剤及び免疫の方法 | |
| Schmidt et al. | The complement-fixing antigen of rubella virus. | |
| US3429965A (en) | Avian pox virus vaccine and process of preparing same | |
| Finlay et al. | The use of the complement fixation test for rapid typing of infectious pancreatic necrosis virus | |
| McCarthy et al. | An Investigation of immunological relationships between the viruses of variola, vaccinia, cowpox and ectromelia by neutralization tests on the chorio-allantois of chick embryos | |
| US3318775A (en) | Production of viral antigens with n-acetyl-ethyleneimine | |
| Musser et al. | Measles virus growth in canine renal cell cultures | |
| Levisohn et al. | Isolation, ultrastructure and antigenicity of Mycoplasma gallisepticum membranes | |
| Fairbrother et al. | Active Immunization against Experimental Influenza: The Use of Heat-killed Elementary Body Suspensions | |
| CN111057683A (zh) | 一种鸡胚接种用病毒稀释液及其制备方法和应用 | |
| JPH0341034A (ja) | ネコ科動物感染性腹膜炎ワクチン | |
| Harris et al. | RELATION OF THE HEMOLYTIC STREPTOCOCCUS TO RHEUMATIC FEVER: IV. Effect of Streptococcic Spreading Factor in Rheumatic Patients and Others | |
| CN105451764A (zh) | 用于制备灭活的轮状病毒的方法 | |
| RU2772751C1 (ru) | Способ получения гипериммунной сыворотки к аденовирусу bovine-10 крупного рогатого скота | |
| Gandhi et al. | Interferon production in cell cultures derived from various chick embryo tissues |